The pharmaceutical sector has changed again! China Pharmaceutical, Zhongsheng Pharmaceutical and other stocks rose to the limit

News on December 16, the pharmaceutical sector has changed again, and from the perspective of individual stocks, it is still a familiar figure
.
Among them, China Pharmaceutical once again rose to the limit, ST Eye Medicine, Zhongsheng Pharmaceutical, etc.
also rose to the limit, in addition, Hendi Pharmaceutical, Xinhua Pharmaceutical, etc.
have risen
sharply.
As of 9:47 on December 16, China National Pharmaceutical rose by 10.
03%, with a quotation of 20.
30 yuan, a turnover of 200 million, and a turnover rate of 0.
66%.

It is worth mentioning that the stock has risen more than 21 times
in the past year.
For the reasons for the change in the stock, the analysis believes that there are several aspects: in terms of pharmaceutical business, the company has established an integrated industrial pattern of trade, industry, technology and service led by international trade, supported by the pharmaceutical industry and linked by pharmaceutical business, comprehensively promoting the business integration of the three major business sectors of industry and commerce and trade, and actively playing synergistic advantages; Its subsidiary, Shenyang Zhuying, is one of the four major suppliers of the B2C section of JD.
com; The company is a state-owned enterprise; The company's industrial system covers chemical preparations, chemical APIs, biological products, Chinese proprietary medicines, Chinese medicine pieces and other pharmaceutical sub-industries, and has a chemical API R & D and production platform, characteristic chemical drugs, modern Chinese medicine R & D and production platform
.
In addition, on the news, China National Pharmaceutical announced on December 14 that the company signed an agreement with Pfizer to be responsible for the import and distribution
of Pfizer's nematevir tablets/ritonavir tablets (Paxlovid) in the Chinese mainland market during the agreement period.
As of 9:47 on December 16, ST eye medicine rose by nearly 5%, the quotation was 9.
07 yuan, the turnover was 4.
9105 million, and the turnover rate was 0.
44%.

The stock has risen more than 10 times
in the past year.
It is understood that ST Eye Medicine belongs to the traditional Chinese medicine manufacturing industry, and the company's main business is pharmaceutical preparations, health care products, and drug circulation
.
The main products include amoxicillin, clavulanate potassium tablets, pearl eye drops, compound fresh bamboo drainage, river car dazuo capsules, Liuwei Rehmannia oral liquid, menthol, menthol oil, Tianmu mountain dendrobium series health care products and dendrobium planting, etc
.
As of 9:47 on December 16, Zhongsheng Pharmaceutical rose to the limit, with a quotation of 35.
33 yuan, a turnover of 2.
059 billion yuan, and a turnover rate of 8.
43%.

The analysis believes that the reasons for the price limit of Zhongsheng Pharmaceutical include: medicine + RAY1216 tablets + generic drugs + medical devices
.
The main business of Zhongsheng Pharmaceutical is drug research and development, production and sales
.
The company's main products are compound thrombosis series products, Zhongsheng pill series products, cefixime dispersible tablets, cefaladine capsules, sucralfate oral suspension
.
On the news, Zhongsheng Pharmaceutical said on the interactive platform on December 16 that the company's cold-related products have increased significantly recently, and some antipyretic and detoxification, antipyretic and analgesic, expectorant and cough products such as Zhongsheng pills, ibuprofen tablets, and dexmethadromethorphan tablets have seriously insufficient
inventory due to the sharp increase in market demand.
At the same time, in response to market demand, the production end has been fully loaded, and does its best to meet market demand
.
In addition, the company announced on November 3 that its innovative drug RAY1216 tablets obtained the ethical approval of the leader of the phase III clinical trial
.
In terms of medical devices, in 2021, the company achieved main business income of 2.
416 billion yuan, a year-on-year increase of 27.
98%, and ophthalmic medical devices and consumables achieved sales of 854,600 yuan, accounting for 0.
04%
of the main business income.
Not long ago, the approval of the consistency evaluation of the quality and efficacy of the generic drug of isoniazid tablets of the company is the embodiment
of the comprehensive strength of the company's and South China Pharmaceutical's R&D capabilities, production and quality management system.
In addition to the above stocks, Hendi Pharmaceutical rose more than 7% and Xinhua Pharmaceutical rose 6.
8%, these two pharmaceutical stocks have recently been very active due to concept themes such as ibuprofen, and are still attracting investors' attention
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.